The Annals Holiday Offer - Save 50%
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 14 April 2004, www.theannals.com, DOI 10.1345/aph.1D335.
 The Annals of Pharmacotherapy: Vol. 38, No. 6, pp. 967-972. DOI 10.1345/aph.1D335
© 2004 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McKenzie, J. E
Right arrow Articles by Cruz-Rivera, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McKenzie, J. E
Right arrow Articles by Cruz-Rivera, M.

PULMONARY

Compatibility of Budesonide Inhalation Suspension with Four Nebulizing Solutions

Jane E McKenzie, PhD

Manager, Analytical Development, QAAS Method Services, AstraZeneca LP, Westborough, MA

Mario Cruz-Rivera, PhD MPH

Development Program Director, Respiratory Drug Development, AstraZeneca LP, Wilmington, DE

Reprints: Jane E McKenzie PhD, AstraZeneca LP, 50 Otis St., Westborough, MA 01581-4500, fax 508/836-8345, jane1.mckenzie{at}astrazeneca.com

BACKGROUND: Nebulizable medications often are mixed to simplify asthma medication regimens.

OBJECTIVE: To establish the in vitro chemical compatibility and stability of budesonide inhalation suspension 0.25 mg/2 mL and 0.5 mg/2 mL mixed in Pari LC Plus jet nebulizer cups with 3 mL of levalbuterol hydrochloride 0.63 mg/3 mL and 1.25 mg/3 mL; 0.5 mL of albuterol sulfate 5 mg/mL; 2 mL of cromolyn sodium 20 mg/2 mL; or 2.5 mL of ipratropium bromide 0.2 mg/mL.

METHODS: We developed and validated isocratic HPLC methods to permit separation of the admixture components from aliquots taken 0, 5, 15, and 30 minutes after mixing. Admixtures were prepared and analyzed at room temperature. Each assay was conducted 3 times using separate nebulizer cups. All components were quantified by external standards using HPLC-derived peak area. Appearance and pH of the admixtures were recorded.

RESULTS: No additional peaks occurred in any HPLC chromatogram for any medication from any admixture. With the exception of ipratropium bromide at 93%, each admixture retained >97% of the initial concentration of each medication in the nebulizer cup. There was no significant change in pH or visual identification of a precipitate in any admixture of active drugs.

CONCLUSIONS: These data support the chemical compatibility of budesonide inhalation suspension for up to 30 minutes with other commonly used nebulized medications for controlling pediatric asthma symptoms.

Key Words: albuterol, asthma, budesonide inhalation suspension

Published Online, April 14, 2004. www.theannals.com, DOI 10.1345/aph.1D335


This article has been cited by other articles:


Home page
 CLIN PEDIATRHome page
M. J. Welch
Nebulization Therapy for Asthma: A Practical Guide for the Busy Pediatrician
Clinical Pediatrics, October 1, 2008; 47(8): 744 - 756.
[PDF]

Home page
 The Annals of PharmacotherapyHome page
S. Akapo, J. Gupta, E. Martinez, C. McCrea, L. Ye, and M. Roach
Compatibility and Aerosol Characteristics of Formoterol Fumarate Mixed with Other Nebulizing Solutions
Ann. Pharmacother., October 1, 2008; 42(10): 1416 - 1424.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2004 by Harvey Whitney Books Company.